ADVFN Logo
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

SPRO Spero Therapeutics Inc

1.438
0.018 (1.27%)
Last Updated: 11:13:54
Delayed by 15 minutes

Period:

Draw Mode:

Volume 61,402
Bid Price 1.43
Ask Price 1.44
News -
Day High 1.4398

Low
0.99

52 Week Range

High
1.995

Day Low 1.388
Company Name Stock Ticker Symbol Market Type
Spero Therapeutics Inc SPRO NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.018 1.27% 1.438 11:13:54
Open Price Low Price High Price Close Price Prev Close
1.42 1.388 1.4398 1.42
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
237 61,402 $ 1.41 $ 86,681 - 0.99 - 1.995
Last Trade Time Type Quantity Stock Price Currency
11:13:54 773 $ 1.438 USD

Spero Therapeutics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
76.49M 53.87M - 103.78M 22.81M 0.42 3.35
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Spero Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No SPRO Message Board. Create One! See More Posts on SPRO Message Board See More Message Board Posts

Historical SPRO Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week1.501.551.371.42229,588-0.062-4.13%
1 Month1.741.811.371.61229,564-0.302-17.36%
3 Months1.531.891.331.66335,613-0.092-6.01%
6 Months1.031.890.991.53248,3130.40839.61%
1 Year1.691.9950.991.52274,306-0.252-14.91%
3 Years13.5819.870.68012.36960,991-12.14-89.41%
5 Years12.3323.6390.68013.56641,635-10.89-88.34%

Spero Therapeutics Description

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

Your Recent History

Delayed Upgrade Clock